Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 32

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 32
---
2 Equity Incentive Plan

On November 6, 2024, our stockholders approved
an amendment to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan (the “2022 Plan”) to increase the number of
shares of Common Stock authorized for issuance by 500,000 shares, which was previously approved by the Board. The total number of shares
reserved under the 2022 Plan is 285,373 shares effective as of February 5, 2025, which additional reservation of shares provides us with
flexibility to address future equity compensation needs. This increase is essential to attract and retain qualified employees, directors
and consultants, and to align their interests with those of our stockholders.

Amendment to Warrants

On September 5, 2024, the Company issued warrants to purchase up to an aggregate of 6,014,493 shares of Common Stock. On September 4, 2024 and November 6, 2024, our Board and stockholders, respectively, approved the exercise of these warrants (the “Warrants Proposal”) in compliance with applicable rules and regulations of the Nasdaq Stock Market LLC. Approval of the exercise of these warrants allows the Company to raise additional funds of up to approximately $4.0 million, providing critical capital to support our operations and growth initiatives. The approval was essential to maintaining compliance with Nasdaq requirements and to support the Company’s long-term financial stability.

<div align='center'>S-17</div>

SUMMARY OF THE OFFERING

| Common stock offered by us                               |     | 1,503,500 shares of common stock at an offering price of $0.715 per                                                                         
 share.                                                                                                                                      |
| Common stock to be outstanding after the offering:(1)(2) |     | 7,364,554 shares of common stock                                                                                                            |
| Use of Proceeds:                                         |     | We intend to use the net                                                                                                                    
 proceeds from this offering for general corporate purposes, among other things, including without limitation, working capital. See          
 “Use of Proceeds” beginning on page S-21.                                                                                                   |
| Risk factors:                                            |     |                                                                                                                                             |
|                                                          |     | You should carefully consider                                                                                                               
 the information set forth in this prospectus and, in particular, the specific factors set forth in the “Risk Factors”                       
 section beginning on page S-20 of this prospectus supplement before deciding whether or not to invest in shares of our Common